Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal Cancer by Gareth, Jenkins
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
World Journal of Surgery
                                     
   





Jones, H., Jenkins, G., Williams, N., Griffiths, P., Chambers, P., Beynon, J. & Harris, D. (2017).  Genetic and













This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 




 ORIGINAL SCIENTIFIC REPORT
Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal
Cancer
Huw Geraint Jones1,5 • Gareth Jenkins3 • Namor Williams2 • Paul Griffiths2 •
Phil Chambers4 • John Beynon1 • Dean Harris1
Published online: 17 January 2017
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Introduction Colorectal cancer (CRC) is a highly heterogeneous disease, with pathologically similar cancers having
completely different responses to treatment and patient survival. Intra-tumour heterogeneity (defined as distinct
morphological and phenotypic differences) has recently been demonstrated to be an important factor in the devel-
opment and behaviour of cancer cells and can be used to determine response to anticancer therapy.
Method Patients with resected CRC had DNA extracted from eight defined tumour areas which were analysed for
two genetic mutations (BRAF and KRAS) and one epigenetic trait (CpG island methylator phenotype/CIMP).
Normal adjacent tissue was studied as control.
Results Twelve patients with CRC were included. Intra-tumoural heterogeneity for KRAS mutation was seen in 2
patients (17%). There was no statistical evidence of CIMP status heterogeneity (p = 0.85), but 6 of the 12 patients
(50%) demonstrated at least one heterogeneous area within the tumour.
Discussion Intra-tumoural heterogeneity for both genetic and epigenetic factors in CRC is more prevalent than pre-
viously thought in Stage II and Stage III CRC. This study provides new insight into epigenetic heterogeneity of CRC
and supports the development of a more targeted biopsy strategy to support expansion of personalised treatment.
Huw Geraint Jones, Gareth Jenkins, Namor Williams, Paul Griffiths,
Phil Chambers, John Beynon and Dean Harris were responsible for
the authorship of this document.
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Introduction
Intra-tumour heterogeneity is defined as the distinct mor-
phological and phenotypic differences within a tumour.
This includes cellular morphology, gene expression, pro-
liferation, metabolism, motility and metastatic potential
[1]. It has been known since the earliest days of cancer cell
biology that phenotypic heterogeneity of cancer cells
within a tumour exists; however, only very recently have
high-resolution genome-wide studies confirmed a great
amount of heterogeneity within individual cancers and
population diversity in mutations involving quantitative
trait loci [2, 3]. This diversity likely represents a Dar-
winian, natural selection model of the clonal evolution of
cancer biology [4]. There are two models used to explain
intra-tumour heterogeneity: the cancer stem cell theory and
the clonal expansion theory. These are not exclusive, and
both are believed to contribute to the process in varying
levels across different cancer types [5].
There is no consensus around what part, or how many
samples of a CRC primary tumour should be sampled in
order to identify potentially prognostic molecular or
histopathological characteristics of a tumour. Baisse et al.
[6] performed a study of 15 patients who were treated
surgically for advanced primary sporadic colorectal ade-
nocarcinoma (Dukes’C or D) in the late 1990s. They
analysed 15–20 areas within the tumour according to the
degree of histological differentiation and depth of invasion
of the tumour. In addition, one sample of normal colonic
mucosa and lymph node metastases was taken for analysis.
The sample location was recorded on a three-dimensional
grid. Samples were tested for gene alterations in KRAS, p53
and LOH in the 5q locus, and 18q locus. They found that
67% of the analysed tumours had tumour heterogeneity in
at least 1 gene locus confirming significant tumour
heterogeneity in advanced CRC, and recommending a
different approach of tumour sampling.
The aim of this study was to establish whether a sig-
nificant level of genetic or epigenetic heterogeneity could
be demonstrated in patients undergoing surgery for col-
orectal cancer. An assessment could therefore be made on
the adequacy of pre-operative biopsies in representing the
whole tumour in terms of the genetic and epigenetic fin-
gerprint, as there are currently no guidelines to support this.
Methodology
Twelve patients having elective surgery for colorectal
cancer between January and June 2014 were randomly
selected in this prospective study. Two pathologists













Fig. 1 Specimen sampling template. *N normal colonic or rectal
tissue adjacent to the tumour
small (\5 cm), as this would have restricted the ability to
sample multiple areas for analysis. None of the patients had
neoadjuvant treatment (radiotherapy or chemotherapy), as
this may have altered the genetic or epigenetic profile of
the tumour. The decision not to give neoadjuvant therapy
was made by the regional multidisciplinary team (MDT)
and was not influenced by the study. This decision was
based on the pre-operative staging of the tumour. There
were no other exclusion criteria, and patients were ran-
domly selected. The tumour sample demographics, site of
tumour, clinical and pathological stage, type of surgery,
type and duration of adjuvant therapy, as well as overall
and disease-free survival were recorded. Ethical approval
for this study was granted by South West Wales REC
(Project Ref No.:11/WA/0256).
Sampling strategy
Two pathologists from Singleton and Morriston Hospitals,
Swansea, sampled the resection specimen in a two-di-
mensional template configuration (Fig. 1).
This resulted in eight areas of the primary tumour being
sampled (proximal, proximal third deep, proximal third
lumen, centre deep, centre lumen, distal third deep, distal
third lumen and distal), as well as one sample of normal
surrounding colonic tissue and of any metastatic lymph
nodes.
DNA extraction
Formalin-fixed paraffin-embedded (FFPE) colorectal can-
cer specimens were utilised for this study. Several repre-
sentative 5-lm sections of the biopsy were cut and
mounted unstained onto glass slides, and DNA from these
tissues was obtained using the MasterPure Complete DNA
and RNA purification kit (Epicentre, Illumina, Wisconsin,
USA).
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The quantity and quality of DNA were measured at
absorbance between 230 and 320 nm using spectropho-
tometry (Nanodrop ND-1000 software version 3.1.2,
Thermoscientific, Delaware, USA). DNA quantity was
calculated by multiplying the measured concentration fol-
lowing spectrophotometry at 260 nm with the dilution
factor. DNA was diluted to a working concentration of
20 ng/ll. Purity was further analysed by calculating the
absorbance at 260 nm to absorbance at 280 nm ratio.
Bisulphite conversion and methylation-specific PCR
(MSP)
MSPwas accomplished by performing bisulphite conversion
of genomic DNA (Imprint DNA Modification Kit, Sigma-
Aldrich, USA). The PCR products were resolved using gel
electrophoresis on a 30% polyacrylamide gel. Depending on
themethylation status of each CpG island, each patient could
be classified as one of three epigenotypes: CIMP-High,
Intermediate or Low using a two-panel approach [7, 8]. The
first panel consists of SOCS1,MINT-1 and hMLH,which are
associated strongly with CIMP-H. The second panel consists
of NEUROG1, THBD, HAND1, ADAMTS1 and IGFBP3.
CIMP status could then be determined using the following
system. All samples were tested in triplicate.
• CIMP-High if C2/3 group 1 markers methylated
• CIMP-Intermediate if\2/3 group 1 but C3/5 group 2
methylated
• CIMP-Low if \2/3 group 1 and \3/5 group 2
methylated.
KRAS and BRAF mutational analysis
Pyrosequencing analysis was performed upon the clinical
specimens of this research project in collaboration with the
Leeds Cancer Research UK Centre (Leeds Institute of
Cancer Studies and Pathology, Clinical Sciences Building,
level 6, St. James’s University Hospital, Leeds, LS9 7TF).
Pyrosequencing conditions used were as previously pub-
lished by this group [9]. Substitution and insertion/deletion
mutations in KRAS codons 12, 13 and 61 and BRAF-600
were examined for all specimens using this method.
Statistics
Statistical analysis was performed using SPSS version 18
(SPSS Inc, Chicago). Data were tested for normality using
Kolmogorov–Smirnov test, and Student’s t test was used
for analysis of normally distributed continuous data. Cat-
egorical variables were compared using Chi-squared [2] or
Fisher’s exact test, where expected frequencies were less
than 10.
Test of CIMP heterogeneity
In the absence of a standard measurement of heterogeneity,
we consulted a statistician working for the School of
Medicine at Swansea University who designed the fol-
lowing simple metric. There are 12 tumours, each of which
has been divided into eight locations (Fig. 1). The adja-
cency rules we imposed mean that of 28 possible pairs of
locations, only 11 would be considered to be adjacent. By
sampling pairs at random, we can count the number of
times the methylation status matches between any two
locations and build up a null distribution for the number of
matches. We take as our test statistic the total number of
matches in methylation status between adjacent locations
in all patients and compare this to our null distribution,
generated by observing randomly chosen pairs. This com-
parison gives us our p-value. The adjacent pairs are listed
below (Fig. 2).
In total, there are 8 9 7 = 56 possible pairs from the
eight observations. The data can now be used to form a
histogram of ‘‘agreements’’, and this will demonstrate if
there is overall heterogeneity (p\ 0.05) or homogeneity
(p[ 0.05) of the sample.
KRAS and BRAF heterogeneity
The degree of KRAS and BRAF heterogeneity was calcu-
lated using basic probability. This probability is our p value
since it represents the chance of seeing such agreement
conditional on the null hypothesis of no association.
Results
Twelve patients with colorectal cancer were included in the
study, with 8 samples being taken from each tumour and
one sample from normal surrounding tissue. Two patients
Fig. 2 Visual representation of adjacent tissue
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(patients 4 and 7) also had lymph node metastases, which
were taken for analysis. Table 1 outlines the patient and
tumour characteristics for the included specimens. There
were three rectal cancers, five left colon/sigmoid cancers
and four right colon cancers. This included ten males and
two female patients with a median age of 70 (range
56–86 years). There were 2 (17%) patients with pAJCC
Stage IV disease (i.e. metastatic disease at the time of
surgery), 7 (58%) patients had Stage II disease, and three
(25%) patients had Stage III disease. Four (33%) patients
had extramural vascular invasion (EMVI) of the tumour,
and nine (66%) had moderately differentiated tumours,
with one poorly differentiated and two well-differentiated
tumours.
Data were also collected on the overall survival (OS)
and disease-free survival (DFS) of the 12 patients with a
note made of the presence of local or systemic recurrence.
As this was a prospective study, the length of follow-up
was relatively short (median 12.5 months). As the number
of included patients is small, no analysis of survival against
tumour factors was performed.
KRAS and BRAF analysis
KRAS and BRAF mutations, determined by pyrosequencing
as previously described, were found to be exclusive of each
other, with no patient having a mutation of both genes
regardless of tumour location. Two patients had a BRAF
mutation (both c.1799T[A/V600E mutations), and both
had tumours located in the right colon. Five of the six
KRAS mutant tumours were in the left colon, sigmoid colon
or rectum (Fig. 3).
Ten of the twelve patients (83%) had a homogenous
distribution of both KRAS and BRAF genotypes. All
BRAF mutations (2 patients) were homogenous in nature,
where two of six (33%) patients with a KRAS mutation
having evidence of intra-tumour heterogeneity. Two
patients (4 and 7) had lymph node metastases, and the
primary tumour and lymph node had same genotype in
both cases. For ease of interpretation, patients have been
ordered by the tumour location (right colon: patients 3, 7,
8 and 9; left colon: patients 2, 4, 5, 6 and 10; rectum:
patients 1, 11 and 12).
CIMP status
Figure 4 demonstrates the CIMP status of all nine locations
for all 12 patients. Both the patients with CIMP-H tumours
had right colon cancers. It is also evident that the normal
tissue surrounding the tumour had a lower CIMP classifi-
cation than the tumour. Six patients (50%) have homoge-
nous tumours in terms of CIMP status by this measure.
There were four normal mucosa specimens (patients 7, 8,
11 and 12) that demonstrated CIMP-Intermediate status.
On histopathological examination, there was no evidence
of tumour cells in these specimens.
Test of CIMP heterogeneity
Figure 5 demonstrates that there is a relationship between
adjacent pairs of tissue [p value = 0.85 (95% CI 0.76,
0.91)]. This suggests that the 12 tumour samples are gen-
erally homogenous in terms of CIMP classification.
Table 1 Patient and tumour characteristics
Patient Age Sex Tumour location Dukes pT pN M pAJCC EMVI CRM ?ve Perforated Cellular diff.
1 60 Male Rectum B 3 0 1 4 0 0 0 Moderate
2 67 Male Splenic C1 3 1 0 2 1 0 1 Well
3 80 Female Caecum B 3 0 0 2 1 0 0 Poor
4 65 Female Sigmoid C1 4 2 0 3 1 0 0 Poor
5 86 Male Sigmoid C1 4 0 0 2 0 0 0 Moderate
6 76 Female Sigmoid B 4 0 0 2 0 0 0 Moderate
7 66 Male Hepatic C1 4 1 0 3 1 0 0 Moderate
8 56 Male Caecum C1 3 0 0 2 0 0 0 Moderate
9 69 Male Ascending B 3 0 0 2 0 0 0 Moderate
10 79 Male Sigmoid C1 3 1 1 4 0 0 0 Moderate
11 75 Male Rectum B 3 0 0 2 0 0 0 Moderate
12 71 Male Rectum C1 3 1 0 3 0 0 0 Moderate
pAJCC pathological American Joint Committee on Cancer Grade, EMVI extramural vascular invasion, CRM circumferential resection margin,
Cellular diff cellular differentiation, M male, F female, R rectum, Sp splenic flexure, C Caecum, Si sigmoid, Hp hepatic flexure, As ascending
colon, W well, Md moderate, P poor
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CIMP status of metastatic lymph nodes
Two patients had metastatic lymph nodes resected at the
index operation (patients 4 and 7). The tumour and lymph
node characteristics are shown in Table 2. There were no
defining genetic or epigenetic factors in these two patients
that differentiated them from patients with non-metastatic
disease. Patient 4 was found to have hepatic metastases
shortly after surgery, and patient 7 currently remains
recurrence-free.
KRAS heterogeneity and CIMP status
As previously mentioned, two patients had heterogeneous
KRAS mutations across the tumour (patients 5 and 11).
When these areas are compared to the CIMP status of those
tumours, the KRAS mutation is seen in areas of hyper-
methylation. Figure 6 demonstrates this, where the areas
within the tumour with mutant KRAS (blue areas) have
higher CIMP status compared with KRAS wild type (grey
areas). Given that we observed three samples with low
Fig. 3 Distribution of the
BRAF and KRAS mutations in
the 12 patients. Patients were
ranked from proximal tumour
location (caecum, patient 3) to
distal (rectal, patient 12)
Fig. 4 CIMP status and tumour
location
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CIMP status, the chance they would all fall on areas with
KRAS wild type (of which there were only 5) can be
calculated using basic probability. This probability is our
p value since it represents the chance of seeing such
agreement conditional on the null hypothesis of no
association.
In patient 5, there is one area within the tumour and
normal tissue proximal to the tumour that is both exclu-
sively CIMP-L and KRAS-wt. The probability of this
occurring spontaneously is 2.8% (1/9 9 1/8). In patient 11,
the chance that the CIMP-L area will be in a KRAS-wt area
is 33% (3/9). Given the situation, we have observed in both
patients and assuming the link was random, we can assign a
p-value of only around 1% (p = 0.009) to this event. There
is therefore a significant association between the two
variables, KRAS mutation and CIMP status.
If only one area of the tumour was tested for a KRAS
mutation from each patient, there would be a 3.13% chance
that the mutation would be missed, based on our 12-patient
sample and the sample being divided into eight equal parts.
If this was increased to two areas, the error rate is reduced
to 0.7%, and this is reduced even further to 0.1% if 3
samples were tested.
Discussion
It is widely recognised that there are founder genetic
mutations common to all cells within a tumour from the
clonal expansion theory of carcinogenesis [10, 11]. With
the recent advances in massively parallel genomic
sequencing, which can define the proportion of a tumour
with any given mutation, there is now definite evidence of
intra-tumour clonal heterogeneity [12]. The driving forces
behind this are as yet unknown; however, genomic insta-
bility is thought of as a potential mechanism [13]. Much
less is known about the role of epigenetics in the car-
cinogenesis sequence, but in the epigenetic progenitor
model, DNA hypermethylation is the root cause of the
Table 2 CIMP status of metastatic lymph nodes
Patient Normal tissue Tumour Lymph node metastases
4 CIMP-L Mostly CIMP-I CIMP-L
7 CIMP-I CIMP-I CIMP-I
Fig. 5 Histogram of CIMP heterogeneity
Fig. 6 KRAS and CIMP status
in patients 5 and 11.
Diagrammatic representation of
KRAS and CIMP status in
patients 5 and 11. Blue areas
represent KRAS mutation, and
grey areas represent KRAS wild
type. The overlaying text
demonstrates CIMP status
(L Low; I Intermediate) and the
corresponding percentage of
methylation
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genomic instability that drives the whole mechanism for-
ward [14]. This suggests a central role of the interplay
between genetic and epigenetic factors [15].
Whatever the underlying cause and exact sequence of
colorectal carcinogenesis, it is becoming increasingly
apparent that there are important clinical implications to
the presence of intra-tumour heterogeneity. This includes a
possible explanation for therapy resistance [16], a need for
greater vigilance while using biopsies to diagnose the
disease, and utilising the presence of heterogeneity as a
biomarker [17]. An understanding of the tumour microen-
vironment is important for the clinician to appreciate, as it
may affect our clinical practice in terms of pre-operative
tumour sampling, as well as guide decisions regarding
future applications of neoadjuvant and adjuvant therapies.
Richman et al. [18] studied 69 primary CRC in 68
patients and demonstrated that 10.1% patients displayed
intra-tumour heterogeneity in KRAS codons 12, 13 and 2 or
BRAF codon 600. Therefore, testing DNA from a single
block will wrongly assign wild-type status to around 10%.
These figures have been replicated by Farber et al. [19].
These papers did not explore the heterogeneity between
specific locations in the tumour, as [6] had done as the
samples had not been mapped at the time of formalin fix-
ation and paraffin embedding (FFPE). Molinari et al. [20]
analysed EGFR gene status and protein expression, as well
as KRAS/BRAF mutations in 38 metastatic CRC. They
found EGFR gene deregulation in 25 out of 36 primary
tumours and 29 out of 36 metastases, KRAS mutations in 16
out of 37 cancers and in 15 out of 37 metastases, and BRAF
mutations in 2 out of 36 cancers and 2 out of 36 metastases.
By doing this analysis, they demonstrated that primary
colorectal cancer and paired metastasis might exhibit dif-
ference with respect to EGFR pathway deregulation
mechanisms, which may lead to differing response to
treatment.
More recently, Fadhil et al. [21] highlighted that
important decisions regarding neoadjuvant treatment are
made from a small biopsy sample from the surface of the
tumour. This could lead to inappropriate and costly errors
in treatment choice. They demonstrated, by comparing
molecular markers such as KRAS, BRAF, PIK3CA, TP53
and MSI, that there was not a significant difference in the
markers found in the biopsy sample and the resection
sample. This study was on a relatively small patient sample
(n = 20), and unfortunately, they failed to adequately
explain which part of the resection sample was tested. This
is a drawback of this study, as it would be expected that a
homogenous result was seen if the same area of the tumour
was sampled in the biopsy and resection specimens.
The results from this work suggest that the majority of
colorectal cancers are largely homogenous in terms of
KRAS, BRAF and CIMP status. Currently, only pre-
operative biopsies for KRAS status have any bearing on
treatment, as the decision to use EGFR-inhibitors is based
on this result. In our sample, 2 of 6 patients with a KRAS
mutation (33%) had some degree of heterogeneity found in
the sample; therefore, a recommendation can be made that
that at least two biopsies from different parts of the tumour
be taken to take the heterogeneity into consideration.
Relationship between genetic and epigenetic changes
Previous work by Jass [22] attempted to combine patterns
of genetic and epigenetic characteristics in colorectal
cancer. Although the final Jass classification is divided into
five groups, he suggested that that CIMP-High CRC was
generally associated with BRAF mutations, KRAS wild
type, a right colon tumour, female predominance and MSI-
H. In contrast, low levels of DNA hypermethylation
(CIMP-Low) were associated with left-sided cancers, a
male predominance, KRAS mutation, BRAF wild type and
MSS. This study generally found this to be true, with both
CIMP-H tumours being located in the right colon and
having BRAF mutations and KRAS wild type. The pres-
ence of CIMP-L was only seen in a heterogeneous fashion
in the left colon and rectum, and this was associated with
KRAS mutation and BRAF wild type. It was not possible to
formally classify the patients into a definite Jass Grouping
[22], as no data were available on the MSI status.
From the relationship seen between the genetic and
epigenetic factors, we can postulate that the epigenetic
changes have occurred later on than the KRAS mutation, as
there was a strong association between the unmethylated
areas with KRAS-wt. This phenomenon was only seen in
two patients, and larger numbers would be needed to
expand on this theory.
Limitations of this study
The large amount of methylation-specific PCR needed (a
minimum of 9 samples per patient, with 8 different gene
promoter regions to test on each sample) limited the
amount of patients in this study to 12. It is possible that we
did not have a representative sample of the general popu-
lation because of this. Other limitations included the
necessity of selecting patients with advanced local disease
(pT3/4) that were not selected for neoadjuvant therapy. The
guidelines state that there is no evidence to support pre-
operative chemotherapy versus surgery alone in patients
with locally advanced colon cancer; however, in the
patients with rectal cancer, chemoradiotherapy before
surgery is recommended for patients with high-risk locally
advanced rectal cancer to allow tumour response and
shrinkage [23]. Of the three patients with rectal cancer
included in the current study, none had any high risks
World J Surg (2017) 41:1375–1383 1381
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outlined in the NICE guidelines, as the specimen had clear
resection margins, and the tumours were not encroaching
on the inter-sphincteric space or the levator ani muscle.
The group of CIMP panel markers that were selected
also limited the results, and it is possible that this is not a
true representation of the CIMP status of the whole gen-
ome. Recent work has established that single-cell genome-
wide bisulphite sequencing is a valid method of measuring
DNA methylation in mice [24]. This technique could be
utilised in humans to aid in the difficult task of measuring
epigenetic heterogeneity in cancer. Analysis of further
mutations (e.g. TP53 and PIC3CA) and microsatellite
instability may have provided further insight into the cause
of intra-tumour heterogeneity.
Conclusion
This pilot study involving 12 patients exploring intra-tu-
mour heterogeneity of colorectal cancer has demonstrated
relative homogeneity of genetic factors (BRAF and KRAS
mutations), as well as epigenetic homogeneity (in terms of
DNA methylation). It has analysed data from a relatively
small number of patients, but importantly, the location of
the biopsies in the tumour was decided according to a
defined template, which investigated mutations based on
tumour topography. It has also revealed interesting patterns
of association of CIMP and KRAS/BRAF mutation in
keeping with the work of Jass [22]. This work further aids
our understanding of the complex process of tumourigen-
esis, and the interweaving role of the genetic and epige-
netic factors.
Clinicians should be aware that at least two pre-opera-
tive biopsies be taken to avoid mis-sampling when
assessing KRAS status. This number may well increase in
future if the CIMP status is found to be clinically signifi-
cant as a prognostic marker.
Current research is focusing on both KRAS and BRAF
as predictive and diagnostic biomarkers in patients with
metastatic disease treated with anti-EGFR therapies, such
as panitumumab and cetuximab [25–27]. As these therapies
become more sophisticated, and the era of personalised
medicine arrives, it becomes increasingly important that
we correctly assess the genetic and epigenetic profile of the
disease. Further work in this area should focus on testing a
greater number of samples, as well as to explore the
heterogeneity in both early and late disease.
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